Breast Cancer Coverage from Every Angle

Helena Margaret Earl, MBBS, PhD, on Adjuvant Trastuzumab in HER2-Positive Early Breast Cancer

Posted: Monday, June 4, 2018

Helena Margaret Earl, MBBS, PhD, of the University of Cambridge, discusses phase III study findings on 6 vs 12 months of adjuvant trastuzumab in patients with HER2-positive early breast cancer.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.